Atlassian uses cookies to improve your browsing experience, perform analytics and research, and conduct advertising. Accept all cookies to indicate that you agree to our use of cookies on your device. Atlassian cookies and tracking notice, (opens new window)
Welcome to the PHUSE Advance Hub
Teams
, (opens new window)

WORKING GROUPS
Results will update as you type.
  • Working Groups
  • Hot Topics
  • Useful Information
  • Deliverables
  • Working Groups Events
  • Working Groups Report – Q3 2025
  • Working Groups Archive
    • Data Transparency Archive
    • Data Visualisation & Open Source Technology Archive
    • Emerging Trends & Technologies Archive
    • Nonclinical Topics Archive
    • Optimizing the Use of Data Standards Archive
      • Best Practices in Data Standards Implementation Governance
      • (BIMO) Bio-research Monitoring Data Reviewer's Guide
      • Dataset-JSON as Alternative Transport Format for Regulatory Submissions
      • FDA Oncology Safety Data Standards
        • FDA Oncology Full Consolidated Comments
      • Implementation of Estimands (ICH E9 (R1)) using Data Standards
      • Standardizing Data within the Inspection Site Selection Process
    • Risk Based Quality Management Archive
    • Real World Evidence Archive
    • Therapeutic Areas
    • Good Programming Practice Project Team
    • Working Group Report Archive
    • Safety Analytics Archive
  • Working Groups Events Archive
    You‘re viewing this with anonymous access, so some content might be blocked.
    /
    FDA Oncology Safety Data Standards

      FDA Oncology Safety Data Standards

      Oct 07, 2024

      Project Scope 

      The goals of this project is to obtain broad industry and CRO feedback on the current publicly available OCE/OOD standard safety data request (found at: https://www.fda.gov/media/133252/download) and assist with the development of resources to assist Sponsors with implementation of these data specifications.

      There is tremendous variability and inconsistency in the use of the CDISC ADaM data standard in safety datasets for oncology NDA/BLA applications submitted to FDA. This variability leads to inefficiency in review for the FDA and multiple information requests to applicants during the course of the review to resolve inconsistencies in analyses between FDA and applicants. The Oncology Centre of Excellence (OCE)/Office of Oncologic Diseases (OOD) has developed a pilot standard safety data request for datasets submitted with NDA/BLA applications and instructions for conducting select safety analyses to create a common set of data elements with common use of these variables for safety analyses. The Stakeholders include FDA reviewers and analysts, industry, CROs, and software developers.

      CURRENT STATUS Q3/4 2022

      This project is currently on hold, the team will reach out for volunteers for the kick off of phase 2

      Project LeadsEmail
      Abhilasha Nairabhilasha.nair@fda.hhs.gov
      Chris Pricechris.price@phuse.global 
      Peter Schotland

      peter.schotland@fda.hhs.gov

      Katie Warren

      (PHUSE Project Assistant)

      katie@phuse.global
      DeliverablesTimelines
      Feedback on publicly available OCE/OOD safety data request.Q2 2021
      Development of basic resources for sponsors to assist implementation (e.g. CRF design to collect relevant data and linkages for adverse events and dataset preparation for laboratory analyses or other resources requested or found to be needed during the feedback process).Q2 2021
      , multiple selections available,
      {"serverDuration": 11, "requestCorrelationId": "e93a6f0177c0404eae676413130c0a18"}